News coverage about XBiotech (NASDAQ:XBIT) has trended somewhat negative this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. XBiotech earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.4141260471883 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of XBiotech traded up $0.18, reaching $4.15, during mid-day trading on Friday, Marketbeat.com reports. 37,576 shares of the stock were exchanged, compared to its average volume of 39,617. XBiotech has a one year low of $3.69 and a one year high of $5.80.
Separately, ValuEngine upgraded XBiotech from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
In related news, Director W Thorpe Mckenzie sold 62,524 shares of the stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $3.98, for a total transaction of $248,845.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 93,531 shares of company stock valued at $377,710. 37.00% of the stock is owned by corporate insiders.
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Further Reading: How do investors use RSI to grade stocks?
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.